➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Boehringer Ingelheim
McKinsey
Merck
Harvard Business School

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TROPICAMIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Tropicamide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00120432 ↗ Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation Completed Khon Kaen University Phase 3 2004-12-01 The purpose of this study is to compare the efficacy on pupillary dilation between the single dose versus the three doses of 1% tropicamide with 10% phenylephrine for complete ocular examination.
NCT00500344 ↗ CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography Unknown status Genentech, Inc. Phase 1 2007-07-01 CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
NCT00500344 ↗ CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography Unknown status Washington University School of Medicine Phase 1 2007-07-01 CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
NCT00501878 ↗ 2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides Completed Khon Kaen University Phase 4 2007-05-01 To compare the clinical efficacy and systemic side effects between 2.5% and 10% phenylephrine for mydriasis in diabetic patient with darkly pigmented irides.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tropicamide

Condition Name

Condition Name for Tropicamide
Intervention Trials
Mydriasis 6
Cataract 3
Retinopathy of Prematurity 2
Dilation 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tropicamide
Intervention Trials
Mydriasis 11
Dilatation, Pathologic 3
Cataract 3
Retinal Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tropicamide

Trials by Country

Trials by Country for Tropicamide
Location Trials
United States 9
France 4
Thailand 3
Belgium 1
Greece 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tropicamide
Location Trials
North Carolina 2
Massachusetts 2
New York 1
California 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tropicamide

Clinical Trial Phase

Clinical Trial Phase for Tropicamide
Clinical Trial Phase Trials
Phase 4 12
Phase 3 8
Phase 2 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tropicamide
Clinical Trial Phase Trials
Completed 10
Not yet recruiting 8
Recruiting 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tropicamide

Sponsor Name

Sponsor Name for Tropicamide
Sponsor Trials
Khon Kaen University 3
Eyenovia Inc. 3
NeuroHealing Pharmaceuticals Inc. 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tropicamide
Sponsor Trials
Other 25
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Baxter
McKesson
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.